Pharmacovigilance Training in 2026: Course Programme

Updated 15 July 2026.

Pharmacovigilance training in 2026 should build more than awareness of terminology: it should demonstrate that personnel can perform the drug-safety activities assigned to their roles. The curriculum must reflect applicable legislation, the organisation’s product portfolio and its pharmacovigilance system.

Core pharmacovigilance competencies

• intake, validation, follow-up and processing of individual case safety reports (ICSRs);
• seriousness, expectedness and causality assessment, plus MedDRA coding;
• medical-literature searching and monitoring of digital sources;
• signal detection, validation, prioritisation, assessment and communication;
• PSUR/PBRER, DSUR and risk management plan (RMP) preparation;
• pharmacovigilance system master file (PSMF), deviations and CAPA;
• audit and inspection readiness, vendor oversight and safety agreements.

Recommended course programme

A practical programme normally covers pharmacovigilance foundations and GVP, the ICSR lifecycle, signal management, risk management, aggregate reporting, quality systems and regulatory timelines. Clinical-trial personnel require a dedicated safety module aligned with the protocol, ICH E6(R3) and local requirements.

Topics that matter in 2026

• RWD and RWE: planning and assessing non-interventional studies with reference to ICH M14.
• Digital channels: websites, social media and mobile applications, including correct routing of safety information.
• Artificial intelligence: tool validation, privacy, traceability, explainability and meaningful human oversight.
• Modernised reporting: change management and preparation for ICH E2D(R1).

Role-based training matrix

All personnel need introductory training on recognising and forwarding safety information. Advanced modules apply to PV operations, medical reviewers, QPPVs and local safety contacts. Tailored modules are also needed for medical information, quality, product complaints, commercial teams, IT and data management. Management should understand governance, resourcing and performance indicators.

How to manage training and demonstrate effectiveness

1. Perform a training-needs analysis and maintain a role–competency–frequency matrix.
2. Complete onboarding before personnel perform duties independently.
3. Provide periodic and change-driven training after regulatory, procedural or system updates.
4. Test knowledge with assessments and practical cases; retrain where necessary.
5. Retain curricula, materials, versions, attendance, results and evidence of competence.
6. Measure effectiveness through ICSR quality, compliance with timelines, audit results and recurring-error trends.

How to choose a pharmacovigilance course

Check that the syllabus matches the learner’s jurisdiction and responsibilities, that instructors have relevant experience, and that practical exercises and objective knowledge assessment are included. A certificate records course completion; it does not replace the employer’s documented competence assessment.

Official resources

• WHO pharmacovigilance and global strategies.
• EMA Good Pharmacovigilance Practices (GVP).
• ICH efficacy and safety guidelines.
• CIOMS pharmacovigilance working groups and publications.

Training with PharmExpert

PharmExpert develops role- and process-specific programmes and provides GVP training and practical workshops on ICSRs, signals, RMPs, PSMFs, audits and inspections. Scope and applicable requirements are agreed with each client.

This article is for general information. Training requirements should be checked against current legislation in the relevant jurisdiction and the organisation’s procedures.